[Pharmacokinetics of generic dasatinib in the management of chronic myeloid leukemia in the choronie phase].

Abstract

Objective: To evaluate the pharmacokinetics and bioequivalence of generic dasatinib in patients with chronic myeloid leukemia in the choronie phase (CML-CP). Methods: Using randomized, parallel, overlapping, self-control designed study, a 100 mg dose of the reference or test tablet was given to 12 CML-CP patients who were resistant or intolerant to Imatinib… (More)
DOI: 10.3760/cma.j.issn.0253-2727.2016.11.006

Topics

  • Presentations referencing similar topics